Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.51 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
| ▸ | QDPR | P09417 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.43 |
| ▸ | HTR1A | P08908 | 2/20 | 0.43 |
| ▸ | TNKS | O95271 | 2/20 | 0.42 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.42 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.42 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL240518 | 0.89 | HTR2C (0.62) | HTR2CSLC18A3SIGMAR1HTR3AQDPR | |
| Hydrochloric Acid SCHEMBL377800 | 0.87 | HTR2C (0.63) | HTR2CSLC18A3SIGMAR1HTR3AQDPR | |
| SCHEMBL1237703 | 0.81 | HTR2C (0.55) | HTR2CSLC18A3SIGMAR1HTR3AQDPR | |
| Hydrochloric Acid SCHEMBL6809356 | 0.79 | HTR2C (0.44) | HTR2CSLC18A3SIGMAR1TNKSTNKS2 | |
| SCHEMBL3045406 | 0.79 | HTR2C (0.51) | HTR2CSLC18A3SIGMAR1QDPRSLC6A2 | |
| SCHEMBL3040992 | 0.79 | SLC6A2 (0.62) | HTR2CSLC18A3SIGMAR1SLC6A2SLC6A4 | |
| SCHEMBL2937820 | 0.77 | HTR3A (0.66) | HTR2CSLC18A3SIGMAR1HTR3A | |
| SCHEMBL1707108 | 0.77 | HTR3A (0.66) | HTR2CSLC18A3SIGMAR1HTR3A | |
| SCHEMBL1828844 | 0.77 | HTR3A (0.66) | HTR2CSLC18A3SIGMAR1HTR3A | |
| SCHEMBL27479343 | 0.76 | HTR2C (0.49) | HTR2CSLC18A3SIGMAR1HTR3AQDPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1444202-B1 | NOVEL METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-10-15 | — | — | EP | disclosed |
| US-7132434-B2 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2006-11-07 | — | — | US | disclosed |
| US-20050026990-A1 | Novel metalloproteinase ihibitors | ASTRAZENECA AB (SE) | 2005-02-03 | — | — | US | disclosed |
| EP-1444202-A1 | NOVEL METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003040098-A1 | NOVEL METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026990-A1 | Novel metalloproteinase ihibitors | MMP12, MMP1, MMP16 | HTR2C 4220/4885SLC18A3 4114/4885SIGMAR1 4738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.